Radiation and Melanoma: Where Are We Now?

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-01 DOI:10.1007/s11912-024-01557-y

Roy Bliley, Adam Avant, Theresa M Medina, Ryan M Lanning

{"title":"Radiation and Melanoma: Where Are We Now?","authors":"Roy Bliley, Adam Avant, Theresa M Medina, Ryan M Lanning","doi":"10.1007/s11912-024-01557-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review summarizes the current role of radiotherapy for the treatment of cutaneous melanoma in the definitive, adjuvant, and palliative settings, and combinations with immunotherapy and targeted therapies.Recent findings: Definitive radiotherapy may be considered for lentigo maligna if surgery would be disfiguring. High risk, resected melanoma may be treated with adjuvant radiotherapy, but the role is poorly defined since the advent of effective systemic therapies. For patients with metastatic disease, immunotherapy and targeted therapies can be delivered safely in tandem with radiotherapy to improve outcomes. Radiotherapy and modern systemic therapies act in concert to improve outcomes, especially in the metastatic setting. Further prospective data is needed to guide the use of definitive radiotherapy for lentigo maligna and adjuvant radiotherapy for high-risk melanoma in the immunotherapy era. Current evidence does not support an abscopal response or at least identify the conditions necessary to reliably produce one with combinations of radiation and immunotherapy.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"904-914"},"PeriodicalIF":4.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01557-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review summarizes the current role of radiotherapy for the treatment of cutaneous melanoma in the definitive, adjuvant, and palliative settings, and combinations with immunotherapy and targeted therapies.

Recent findings: Definitive radiotherapy may be considered for lentigo maligna if surgery would be disfiguring. High risk, resected melanoma may be treated with adjuvant radiotherapy, but the role is poorly defined since the advent of effective systemic therapies. For patients with metastatic disease, immunotherapy and targeted therapies can be delivered safely in tandem with radiotherapy to improve outcomes. Radiotherapy and modern systemic therapies act in concert to improve outcomes, especially in the metastatic setting. Further prospective data is needed to guide the use of definitive radiotherapy for lentigo maligna and adjuvant radiotherapy for high-risk melanoma in the immunotherapy era. Current evidence does not support an abscopal response or at least identify the conditions necessary to reliably produce one with combinations of radiation and immunotherapy.

查看原文本刊更多论文

辐射与黑色素瘤：我们现在在哪里？

综述的目的：本综述总结了目前放射治疗在皮肤黑色素瘤的根治性、辅助性和姑息性治疗中的作用，以及与免疫疗法和靶向疗法的结合：最新研究结果：如果手术会造成毁容，则可考虑对恶性白斑病进行最终放疗。高风险、已切除的黑色素瘤可采用辅助放疗，但自有效的全身疗法出现以来，这种疗法的作用尚不明确。对于转移性疾病患者，免疫疗法和靶向疗法可与放疗同时安全进行，以改善疗效。放疗与现代全身疗法的协同作用可提高疗效，尤其是在转移性疾病中。在免疫疗法时代，需要进一步的前瞻性数据来指导对恶性白斑的最终放疗和对高危黑色素瘤的辅助放疗。目前的证据并不支持腹水反应，或者至少不能确定在放射治疗和免疫治疗联合应用的情况下产生腹水反应的必要条件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.